Adam B Weiner1, Sanjay G Patel2, Ruth Etzioni3, Scott E Eggener4. 1. Pritzker School of Medicine, University of Chicago, Chicago, Illinois. 2. Section of Urology, University of Chicago, Chicago, Illinois. 3. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. 4. Department of Surgery, University of Chicago, Chicago, Illinois. Electronic address: seggener@surgery.bsd.uchicago.edu.
Abstract
PURPOSE: To our knowledge factors affecting the adoption of noncurative initial management in the United States for low risk prostate cancer on a population based level are unknown. We measured temporal trends in the proportion of patients with low and intermediate risk prostate cancer who elected noncurative initial treatment in the United States and analyzed the association of factors affecting management choice. MATERIALS AND METHODS: We identified 465,591 and 237,257 men diagnosed with low or intermediate risk prostate cancer using NCDB and SEER (2004 to 2010), respectively. We measured the proportion of men who elected noncurative initial treatment and used multivariate logistic regression analysis to evaluate factors affecting the treatment choice. RESULTS: During the study period noncurative initial management increased in patients at low risk from 21% to 32% in SEER and from 13% to 20% in NCDB (each p < 0.001). This increase was not reflected in our overall study population (SEER 20% to 22% and NCDB 11% to 13%) since the proportion of patients with Gleason score 6 or less decreased with time (61% to 49% and 61% to 45%, respectively). From 2004 to 2010 older age, lower prostate specific antigen, earlier clinical stage, increased comorbidity index and not being married were associated with a higher likelihood of noncurative initial management (each p < 0.05). CONCLUSIONS: Two independently managed, population based data sets confirmed a temporal increase in noncurative initial management in patients with low risk PCa that did not translate into greater use overall in those at low and intermediate risk combined. These contrasting results are likely due to grade migration resulting in fewer men being classified as with low risk PCa based on Gleason score.
PURPOSE: To our knowledge factors affecting the adoption of noncurative initial management in the United States for low risk prostate cancer on a population based level are unknown. We measured temporal trends in the proportion of patients with low and intermediate risk prostate cancer who elected noncurative initial treatment in the United States and analyzed the association of factors affecting management choice. MATERIALS AND METHODS: We identified 465,591 and 237,257 men diagnosed with low or intermediate risk prostate cancer using NCDB and SEER (2004 to 2010), respectively. We measured the proportion of men who elected noncurative initial treatment and used multivariate logistic regression analysis to evaluate factors affecting the treatment choice. RESULTS: During the study period noncurative initial management increased in patients at low risk from 21% to 32% in SEER and from 13% to 20% in NCDB (each p < 0.001). This increase was not reflected in our overall study population (SEER 20% to 22% and NCDB 11% to 13%) since the proportion of patients with Gleason score 6 or less decreased with time (61% to 49% and 61% to 45%, respectively). From 2004 to 2010 older age, lower prostate specific antigen, earlier clinical stage, increased comorbidity index and not being married were associated with a higher likelihood of noncurative initial management (each p < 0.05). CONCLUSIONS: Two independently managed, population based data sets confirmed a temporal increase in noncurative initial management in patients with low risk PCa that did not translate into greater use overall in those at low and intermediate risk combined. These contrasting results are likely due to grade migration resulting in fewer men being classified as with low risk PCa based on Gleason score.
Authors: Richard M Hoffman; Stephen K Van Den Eeden; Kimberly M Davis; Tania Lobo; George Luta; Jun Shan; David Aaronson; David F Penson; Amethyst D Leimpeter; Kathryn L Taylor Journal: Psychooncology Date: 2017-07-13 Impact factor: 3.894
Authors: Ronald E Myers; Amy E Leader; Jean Hoffman Censits; Edouard J Trabulsi; Scott W Keith; Anett M Petrich; Anna M Quinn; Robert B Den; Mark D Hurwitz; Costas D Lallas; Sarah E Hegarty; Adam P Dicker; Charnita M Zeigler-Johnson; Veda N Giri; Hasan Ayaz; Leonard G Gomella Journal: J Cancer Educ Date: 2018-02 Impact factor: 2.037
Authors: Chad Tang; Karen E Hoffman; Pamela K Allen; Molly Gabel; David Schreiber; Seungtaek Choi; Brian F Chapin; Quynh-Nhu Nguyen; John W Davis; Paul Corn; Christopher Logothetis; John Ward; Steven J Frank; Neema Navai; Sean E McGuire; Mitchell Anscher; Louis Pisters; Curtis A Pettaway; Rachit Kumar; Patrick Linson; Prabhakar Tripuraneni; Jeffrey J Tomaszewski; Ashish B Patel; Mark Augspurger; Deborah A Kuban Journal: Cancer Date: 2019-11-19 Impact factor: 6.860
Authors: Richard M Hoffman; Ying Shi; Stephen J Freedland; Nancy L Keating; Louise C Walter Journal: Cancer Epidemiol Date: 2015-07-27 Impact factor: 2.984